Medicare Enrolled
Dr. Ahmed Al-Hazzouri, M.D.
Medical Oncology · Clermont, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Al-Hazzouri from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Al-Hazzouri? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Al-Hazzouri
Dr. Ahmed Al-Hazzouri is a medical oncology in Clermont, FL, with 18 years in practice. Based on federal Medicare data, Dr. Al-Hazzouri performed 293,813 Medicare services across 6,282 unique beneficiaries.
Between the years covered by Open Payments, Dr. Al-Hazzouri received a total of $31,851 from 68 pharmaceutical and/or device companies across 455 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Al-Hazzouri is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice▲ Top 6% volume in FL$ $31,851 industry payments
Medicare Practice Summary
Medicare Utilization ↗293,813
Medicare services
Top 6% in FL for medical oncology
6,282
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~16,323 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 51,510 | $0 | $4 |
| Nivolumab injection (Opdivo) | 44,440 | $24 | $72 |
| Iron sucrose injection (Venofer) | 31,600 | $0 | $5 |
| Pembrolizumab injection (Keytruda) | 29,600 | $43 | $137 |
| Anti-nausea injection (aprepitant) | 23,400 | $1 | $5 |
| Azacitidine chemotherapy injection | 21,843 | $0 | $4 |
| Paclitaxel chemotherapy injection | 19,017 | $0 | $2 |
| Filgrastim injection (Zarxio) for white blood cells | 15,120 | $0 | $2 |
| Epoetin alfa injection (Procrit) for anemia | 10,030 | $6 | $23 |
| Denosumab injection (Prolia/Xgeva) | 8,100 | $18 | $51 |
| Immune globulin infusion (Gammagard) | 4,498 | $36 | $108 |
| Dexamethasone injection (steroid) | 4,316 | $0 | $3 |
| Complete blood count (CBC) with differential | 3,491 | $8 | $29 |
| Blood draw (venipuncture) | 3,216 | $8 | $9 |
| Anti-nausea injection (Aloxi/palonosetron) | 3,180 | $1 | $28 |
| Injection, eflapegrastim-xnst, 0.1 mg | 3,036 | $27 | $116 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 3,000 | $22 | $185 |
| Office visit, established patient (30-39 min) | 1,594 | $94 | $339 |
| Office visit, established patient (20-29 min) | 963 | $63 | $239 |
| Injection, leucovorin calcium, per 50 mg | 930 | $3 | $12 |
| Administration of chemotherapy into vein, 1 hour or less | 892 | $97 | $378 |
| Drug injection, under skin or into muscle | 781 | $10 | $69 |
| Injection, zoledronic acid, 1 mg | 762 | $6 | $69 |
| Injection of additional new drug or substance into vein | 725 | $12 | $61 |
| Anti-nausea injection (ondansetron/Zofran) | 664 | $0 | $9 |
| Injection, carboplatin, 50 mg | 654 | $2 | $41 |
| Injection, fluorouracil, 500 mg | 598 | $2 | $7 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 581 | $3 | $205 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 569 | $22 | $84 |
| Cyclophosphamide, 100 mg | 496 | $16 | $79 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 433 | $47 | $189 |
| Injection, diphenhydramine hcl, up to 50 mg | 368 | $1 | $3 |
| Administration of additional new drug or substance into vein, 1 hour or less | 329 | $49 | $178 |
| Administration of chemotherapy into vein, each additional hour | 314 | $21 | $79 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 283 | $55 | $206 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 234 | $136 | $562 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 199 | $1 | $6 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 178 | $15 | $56 |
| Injection of drug or substance into vein | 166 | $26 | $156 |
| Initial hospital admission, high complexity | 139 | $136 | $556 |
| Prothrombin time test (blood clotting) | 131 | $4 | $15 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 123 | $23 | $89 |
| New patient office visit (30-44 min) | 117 | $84 | $298 |
| Administration of additional new drug or substance into vein using push technique | 110 | $42 | $170 |
| New patient office visit, complex (60-74 min) | 101 | $163 | $585 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 98 | $3 | $11 |
| Infusion, normal saline solution , 1000 cc | 89 | $2 | $7 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 88 | $15 | $56 |
| Injection, leuprolide acetate for depot suspension (cipla), 7.5 mg | 81 | $300 | $1,210 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 80 | $15 | $59 |
| Infusion into a vein for hydration, each additional hour | 72 | $10 | $42 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 71 | $126 | $637 |
| Infusion into a vein for hydration, 31-60 minutes | 60 | $25 | $156 |
| Automated urinalysis | 58 | $2 | $8 |
| Office visit, established patient, complex (40-54 min) | 55 | $140 | $474 |
| New patient office visit (45-59 min) | 52 | $120 | $453 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 51 | $1 | $7 |
| Hospital follow-up visit, high complexity | 42 | $94 | $285 |
| Drawing of blood for a medical problem | 36 | $66 | $277 |
| Office visit, established patient (10-19 min) | 30 | $42 | $147 |
| Advance care planning consultation, first 30 min | 19 | $65 | $225 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
19.6% high complexity
76.5% medium
3.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$31,851
Total received (2018-2024)
Avg $4,550/year across 7 years
Top 17% in FL for medical oncology
68
Companies
455
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$19,678 (61.8%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,501 (23.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$4,672 (14.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$4,561
2023$2,665
2022$5,871
2021$2,158
2020$3,227
2019$13,045
2018$324
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$8,520
Incyte Corporation
$2,877
Verastem, Inc.
$2,710
BeiGene USA, Inc.
$2,509
AstraZeneca Pharmaceuticals LP
$2,508
NOVARTIS PHARMACEUTICALS CORPORATION
$2,350
Adaptive Biotechnologies Corporation
$1,495
Epizyme, Inc.,
$1,250
Celgene Corporation
$741
Janssen Biotech, Inc.
$725
E.R. Squibb & Sons, L.L.C.
$630
PFIZER INC.
$478
Genentech USA, Inc.
$320
Blueprint Medicines Corporation
$296
Gilead Sciences, Inc.
$296
GENZYME CORPORATION
$267
Daiichi Sankyo Inc.
$243
Astellas Pharma US Inc
$234
Pharmacyclics LLC, An AbbVie Company
$230
Karyopharm Therapeutics Inc.
$214
Merck Sharp & Dohme LLC
$199
GlaxoSmithKline, LLC.
$194
Amgen Inc.
$191
Kite Pharma, Inc.
$157
Seagen Inc.
$153
Pharmacyclics LLC, an AbbVie Company
$133
TerSera Therapeutics LLC
$130
ARRAY BIOPHARMA INC
$127
Merck Sharp & Dohme Corporation
$126
EMD Serono, Inc.
$115
Exelixis Inc.
$92
Sumitomo Pharma America, Inc.
$87
Rigel Pharmaceuticals, Inc.
$76
Myovant Sciences Inc.
$72
Eisai Inc.
$72
Takeda Pharmaceuticals U.S.A., Inc.
$68
ADC Therapeutics America, Inc.
$56
AbbVie Inc.
$54
CTI BioPharma Corp.
$54
G1 Therapeutics, Inc.
$50
Acrotech Biopharma Inc.
$48
Bayer HealthCare Pharmaceuticals Inc.
$44
Seattle Genetics, Inc.
$42
Bayer Healthcare Pharmaceuticals Inc.
$42
Boehringer Ingelheim Pharmaceuticals, Inc.
$40
Taiho Oncology, Inc.
$39
Alnylam Pharmaceuticals Inc.
$38
ABBVIE INC.
$38
TAIHO ONCOLOGY, INC.
$35
SOBI, INC
$34
Teva Pharmaceuticals USA, Inc.
$26
Ipsen Biopharmaceuticals, Inc
$26
Sun Pharmaceutical Industries Inc.
$25
PharmaEssentia USA Corporation
$25
Foundation Medicine, Inc.
$24
Pharmacosmos Therapeutics Inc.
$23
JAZZ PHARMACEUTICALS INC.
$22
AMAG Pharmaceuticals, Inc.
$20
Global Blood Therapeutics, Inc.
$19
GE HealthCare
$19
Horizon Pharma plc
$19
Tempus AI, Inc
$18
Alexion Pharmaceuticals, Inc.
$17
Jazz Pharmaceuticals Inc.
$16
MEDIVATION FIELD SOLUTIONS LLC
$14
Servier Pharmaceuticals LLC
$14
EISAI INC.
$13
Secura Bio, Inc.
$12
Top 3 companies account for 44.3% of total payments
Associated products mentioned in payments ›
ADCETRIS · ALUNBRIG · AYVAKIT · Alecensa · Aliqopa · BAVENCIO · BELEODAQ · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · CABOMETYX · CERDELGA · COSELA · Cabometyx · Copiktra · DARZALEX · Doptelet · ELITEK · ELREXFIO · EPKINLY · ERLEADA · Enhertu · Erleada · FARYDAK · FERAHEME · FOUNDATIONONE · FRUZAQLA · Fabhalta · GAVRETO · GAZYVA · GILOTRIF · GIVLAARI · IBRANCE · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRYSTEXXA · Kadcyla · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lunsumio · MEKINIST · MYLOTARG · Nplate · Nubeqa · ODOMZO · OJJAARA · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · PADCEV · PIQRAY · PROMACTA · Padcev · Phesgo · Pomalyst · REBLOZYL · RYBREVANT · Revlimid · SCEMBLIX · SHINGRIX · SOLIRIS · SOMATULINE DEPOT · Stivarga · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · Tecentriq · Trodelvy · VARUBI · VENCLEXTA · VOTRIENT · Vonjo · XALKORI · XPOVIO · XT CDX · XTANDI · Xermelo · Xtandi · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX · Zoladex · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (62%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Equivalent to $11 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
22
Per 100K population
5.5
County median income
$69,956
Nearest hospital
ORLANDO HEALTH SOUTH LAKE HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Al-Hazzouri is a mixed practice specialist, with above-average Medicare volume (top 6% in FL), and high industry engagement (consulting-driven, top 17%), with 18 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Al-Hazzouri experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Al-Hazzouri performed 51,510 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Al-Hazzouri receive payments from pharmaceutical companies?
Yes. Dr. Al-Hazzouri received a total of $31,851 from 68 companies across 455 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Al-Hazzouri's costs compare to other medical oncologys in Clermont?
Dr. Al-Hazzouri's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Al-Hazzouri) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Clermont
Browse medical oncologys in Clermont ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in FL
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in FL
Which FL medical oncologys receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Incyte Corporation Payments to Doctors
See all physicians who received payments from Incyte Corporation.
By company
Verastem, Inc. Payments to Doctors
See all physicians who received payments from Verastem, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology